Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

Morning Bell 4 April

Sophia Mavridis
April 4, 2023

Morning Bell 3 April

Grady Wulff
April 3, 2023

Weekly Wrap 31 March

Grady Wulff
March 31, 2023

Morning Bell 31 March

Grady Wulff
March 31, 2023

Morning Bell 30 March

Grady Wulff
March 30, 2023

Morning Bell 29 March

Grady Wulff
March 29, 2023

Morning Bell 28 March

Sophia Mavridis
March 28, 2023

Morning Bell 27 March

Grady Wulff
March 27, 2023

Weekly Wrap 24 March

Sophia Mavridis
March 24, 2023

Morning Bell 24 March

Sophia Mavridis
March 24, 2023

Morning Bell 23 March

Sophia Mavridis
March 23, 2023

Morning Bell 22 March

Grady Wulff
March 22, 2023